ATE314069T1 - Antineoplasische kombinationspräparate - Google Patents

Antineoplasische kombinationspräparate

Info

Publication number
ATE314069T1
ATE314069T1 AT02768432T AT02768432T ATE314069T1 AT E314069 T1 ATE314069 T1 AT E314069T1 AT 02768432 T AT02768432 T AT 02768432T AT 02768432 T AT02768432 T AT 02768432T AT E314069 T1 ATE314069 T1 AT E314069T1
Authority
AT
Austria
Prior art keywords
antineoplasic
combination preparations
preparations
combination
antineoplasic combination
Prior art date
Application number
AT02768432T
Other languages
English (en)
Inventor
Sridhar Krishna Rabindran
James J Gibbons Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE314069T1 publication Critical patent/ATE314069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • External Artificial Organs (AREA)
AT02768432T 2001-08-07 2002-08-06 Antineoplasische kombinationspräparate ATE314069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31064601P 2001-08-07 2001-08-07
PCT/US2002/024841 WO2003020266A1 (en) 2001-08-07 2002-08-06 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
ATE314069T1 true ATE314069T1 (de) 2006-01-15

Family

ID=23203475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02768432T ATE314069T1 (de) 2001-08-07 2002-08-06 Antineoplasische kombinationspräparate

Country Status (26)

Country Link
US (4) US6617333B2 (de)
EP (2) EP1671943A1 (de)
JP (2) JP2005505549A (de)
KR (1) KR20040029406A (de)
CN (3) CN101279983A (de)
AR (2) AR036250A1 (de)
AT (1) ATE314069T1 (de)
AU (2) AU2002330994B2 (de)
BR (1) BR0211769A (de)
CA (1) CA2455126A1 (de)
CY (1) CY1104983T1 (de)
DE (1) DE60208385T2 (de)
DK (1) DK1414438T3 (de)
EA (2) EA200501251A1 (de)
ES (1) ES2252512T3 (de)
HU (1) HUP0401089A3 (de)
IL (2) IL159859A0 (de)
MX (1) MXPA04001118A (de)
NO (2) NO325503B1 (de)
NZ (3) NZ530847A (de)
PL (1) PL368303A1 (de)
SG (1) SG170612A1 (de)
TW (2) TWI300351B (de)
UA (1) UA77200C2 (de)
WO (1) WO2003020266A1 (de)
ZA (1) ZA200401801B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP3342411B1 (de) 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin-derivat zur behandlung von bauchspeicheldrüsenkrebs
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP1504010B1 (de) * 2002-05-15 2009-03-25 Endocyte, Inc. Vitamin-mitomycin-konjugate
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
EP2517730A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (de) * 2003-04-22 2007-01-24 Wyeth Antineoplastische zusammensetzungen
EP1648516A2 (de) * 2003-08-01 2006-04-26 Wyeth Holdings Corporation Verwendung einer kombination aus einem epidermalen wachstumsfaktor-rezeptor-kinase-hemmer und zytotoxischen mitteln zur behandlung und hemmung von krebs
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
PL1701698T3 (pl) * 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
SG149817A1 (en) * 2004-01-16 2009-02-27 Wyeth Corp Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
CA2585840A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CN101137748B (zh) 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
JP2008545688A (ja) * 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
MX2007014773A (es) * 2005-05-25 2008-02-20 Wyeth Corp Metodo para preparar 3-ciano-quinolinas e intermedios hechos de esta forma.
CN101180273A (zh) * 2005-05-25 2008-05-14 惠氏公司 合成6-烷基氨基喹啉衍生物的方法
CA2610209A1 (en) * 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ES2449197T5 (es) * 2005-07-01 2022-04-28 Wyeth Llc Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3- quinolincarbonitrilo y procedimientos de preparación de las mismas
EP2382995A3 (de) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligandenkonjugate von Vincaalkaloiden, Analoga und Derivaten
US8465724B2 (en) * 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
KR101354828B1 (ko) * 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh) * 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
CN104382862A (zh) * 2008-12-02 2015-03-04 生物相容英国有限公司 胰腺肿瘤治疗
EP2416774B1 (de) 2009-04-06 2015-11-04 Wyeth LLC Behandlungsschema mit neratinib gegen brustkrebs
MX340985B (es) 2010-09-29 2016-08-01 Intervet Int Bv Compuestos de n-heteroarilo.
EP2621923B1 (de) 2010-09-29 2017-03-29 Intervet International B.V. N-heteroarylverbindungen mit cyclischer überbrückungseinheit zur behandlung von parasitären erkrankungen
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TWI740873B (zh) 2015-12-24 2021-10-01 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU415255A1 (ru) * 1972-03-20 1974-02-15 Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4194050A (en) 1976-04-30 1980-03-18 Sumitomo Chemical Company, Limited Process for producing an enamide
US4195021A (en) 1977-10-26 1980-03-25 Eli Lilly And Company 1,3-Disubstituted 2-azetidinone antibitotics
US4193983A (en) 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
BE897134A (fr) 1983-06-24 1983-12-27 Solvay Dienes polysubstitues
US4478959A (en) 1983-09-29 1984-10-23 Air Products And Chemicals, Inc. Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations
DE3347659A1 (de) 1983-12-31 1985-07-11 Bayer Ag, 5090 Leverkusen Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren
US4664825A (en) 1984-10-25 1987-05-12 The Lubrizol Corporation Sulfurized compositions and lubricants containing them
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
CA2038633A1 (en) 1990-03-20 1991-09-21 Yoshimi Tsuchiya Substituted amine derivatives having anti-hyperlipemia activity
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
CN1069492A (zh) * 1991-08-21 1993-03-03 山之内制药株式会社 4-酰胺基咪唑衍生物
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5352783A (en) 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1318837T3 (da) * 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.

Also Published As

Publication number Publication date
DK1414438T3 (da) 2006-03-27
SG170612A1 (en) 2011-05-30
IL159859A0 (en) 2004-06-20
ZA200401801B (en) 2005-06-06
AU2002330994B2 (en) 2007-10-04
HUP0401089A3 (en) 2007-12-28
TWI300351B (en) 2008-09-01
EP1414438B1 (de) 2005-12-28
DE60208385T2 (de) 2006-08-03
TWI305527B (en) 2009-01-21
US20030050222A1 (en) 2003-03-13
NZ542272A (en) 2007-12-21
US6617333B2 (en) 2003-09-09
AR051778A2 (es) 2007-02-07
CN101279983A (zh) 2008-10-08
CA2455126A1 (en) 2003-03-13
EP1671943A1 (de) 2006-06-21
JP2005505549A (ja) 2005-02-24
WO2003020266A1 (en) 2003-03-13
TW200626526A (en) 2006-08-01
PL368303A1 (en) 2005-03-21
CN1326523C (zh) 2007-07-18
CN1538842A (zh) 2004-10-20
NO20073801L (no) 2004-02-06
USRE40418E1 (en) 2008-07-01
NO325503B1 (no) 2008-05-26
KR20040029406A (ko) 2004-04-06
IL159859A (en) 2009-12-24
NZ530847A (en) 2006-02-24
USRE41084E1 (en) 2010-01-19
JP2010155845A (ja) 2010-07-15
NO20040558L (no) 2004-02-06
BR0211769A (pt) 2004-07-27
EA200400284A1 (ru) 2004-06-24
AR036250A1 (es) 2004-08-25
EA011098B1 (ru) 2008-12-30
HK1061204A1 (en) 2004-09-10
CN100415753C (zh) 2008-09-03
CN1803806A (zh) 2006-07-19
MXPA04001118A (es) 2004-05-20
CY1104983T1 (el) 2010-03-03
HUP0401089A2 (hu) 2004-09-28
ES2252512T3 (es) 2006-05-16
USRE41253E1 (en) 2010-04-20
NZ560845A (en) 2008-09-26
DE60208385D1 (de) 2006-02-02
AU2006233165A1 (en) 2006-11-09
EA006226B1 (ru) 2005-10-27
AU2006233165B2 (en) 2009-12-24
EA200501251A1 (ru) 2008-12-30
UA77200C2 (en) 2006-11-15
EP1414438A1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
DE60208385D1 (de) Antineoplasische kombinationspräparate
NO20033556D0 (no) Farmasöytiske preparater
DE60222056D1 (de) Hebestuhl
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE60214255D1 (de) Schlussstück
ATE335486T1 (de) Hydrazono-malonitrile
DE50209245D1 (de) Neuroprotektives medikament
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20014597D0 (no) Fremgangsmåte
ATE355059T1 (de) Isoxazolopyridinone
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
ATA13992002A (de) Schlackengranulierungsanlage
DE60229395D1 (de) Altung
DE10295006D2 (de) Bauwerksabdichtung
ATA2892002A (de) Beschlag
ATE405973T1 (de) Steckverbindung
AT500276B1 (de) Radschwenksystem
ATE345337T1 (de) Delta1 -pyrroline
NO20041687L (no) Sluttstykke
ATA7462001A (de) Radspannwerk
DE10142202B8 (de) Hochvakuumbedampfungsanlage
ATA6162001A (de) Schneekette
UA5162S (uk) Крісло
FI5386U1 (fi) Jyrsin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414438

Country of ref document: EP

REN Ceased due to non-payment of the annual fee